BioCentury
ARTICLE | Clinical News

RP101: Additional Phase I/II data

September 26, 2005 7:00 AM UTC

Additional data from a previously reported open-label, German Phase I/II trial in 13 patients showed that 10 of the 13 patients taking 500 mg daily RP101 plus gemcitabine/cisplatin survived at least 1...